A Research on Hidden Blood Loss in Open Radical Hysterectomy and Pelvic Lymphadenectomy

October 27, 2020 updated by: Second Affiliated Hospital of Wenzhou Medical University
The aim of this cross-sectional study is to evaluate the hidden blood loss in patients who underwent open radical hysterectomy and identity its risk factors.

Study Overview

Status

Unknown

Conditions

Detailed Description

The electronic medical data of 100 patients who undergo open radial hysterectomy in the following year to treat cervical cancer will be analyzed retrospectively in this study. The amount of hidden blood loss will be calculated according to Gross's formula. And multiple linear regression analysis will be employed to identify its risk factors.

Study Type

Observational

Enrollment (Anticipated)

105

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Zhejiang
      • Wenzhou, Zhejiang, China, 325000
        • TING LI

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

The planned sample size was based on data from a previous study, in which the standard deviation was 5. We assumed an one-tailed α error of 0.05 and a sampling error of 1.0. we propose to enroll 105 participants and allow for a dropout rate of 10% for an effective sample size of 100.

Description

Inclusion Criteria:

  1. Volunteer to participate in the study with informed consent;
  2. Females aged 20-80 who are confirmed with cervical cancer and are treated with open radical hysterectomy and pelvic lymphadenectomy.

Exclusion Criteria:

  1. Pregnancy, lactation, postmenopause, or planned pregnancy within two years;
  2. Suspected or identified as other tumors of genital tract;
  3. History of hyperparathyroidism, infectious diseases (tuberculosis, AIDS), autoimmune diseases, or digestive system diseases (malabsorption, crohn disease and dysentery);
  4. Other diseases or heavy injuries that will interfere with the results;
  5. Simultaneous participation in another clinical study with investigational medicinal product(s) or researcher thinks the subjects are not suitable for this trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
open radical hysterectomy
The patients who would undergo "open radical hysterectomy" procedure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the volume of hidden blood loss (mL)
Time Frame: 10 months after surgery
the volume of invisible blood loss occurring in patients who undergo open radical hysterectomy applying Gross's formula
10 months after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the risk factors of hidden blood loss
Time Frame: 10 months after surgery
Performing multiple linear regression analysis with SPSS 17.0, we plan to identify the factors which may increase the volume of hidden blood loss from possible factors like hypertension, diebetes, etc.
10 months after surgery
the volume of total blood loss (mL)
Time Frame: 10 months after surgery
the vomule of patients' blood loss through the whole perioperative time according to the method of Nadler
10 months after surgery
the volume of visible blood loss (mL)
Time Frame: 10 months after surgery
the visible blood loss including the blood in the suction bottle and in weighed compresses during the operation and the drainage volume after the operation
10 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Second Affiliated Hospital of Wenzhou Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

September 1, 2022

Primary Completion (ANTICIPATED)

September 1, 2022

Study Completion (ANTICIPATED)

September 1, 2022

Study Registration Dates

First Submitted

August 5, 2018

First Submitted That Met QC Criteria

August 8, 2018

First Posted (ACTUAL)

August 14, 2018

Study Record Updates

Last Update Posted (ACTUAL)

October 29, 2020

Last Update Submitted That Met QC Criteria

October 27, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SAHoWMU-CR2018-07-130

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cervical Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe